Novo Nordisk clinical trial pipeline

9 trials changed in the last 30 days: 0 stopped, 7 with notable changes, 2 with minor changes only.

1. Notable: Research Study Looking Into Blood Levels of the Medicine…Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated · Reduced Liver Function and Normal Liver Function Nov 10, 2026 Recruitment opened Novo Nordisk A/S·Phase 1· NCT07587710
2. Notable: Research Study to Check the Safety of NNC9836-0001 When Given…Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and · Type 2 Diabetes Nov 10, 2026 Recruitment opened Novo Nordisk A/S·Phase 1· NCT07896109
3. Minor: AMAZE 8 · NNC0487-0111 Compared to Semaglutide Helps · Excess…AMAZE 8 · NNC0487-0111 Compared to Semaglutide Helps · Excess Body Weight and Type 2 Diabetes Lose Weight Nov 10, 2026 Trial status changed: Not Yet Recruiting → Active, Not Recruiting Novo Nordisk A/S·Phase 3· NCT07400107
4. Minor: AMAZE 2 · NNC0487-0111 Helps · Excess Body Weight and Type 2…AMAZE 2 · NNC0487-0111 Helps · Excess Body Weight and Type 2 Diabetes Lose Weight Nov 6, 2026 Enrollment closed, study ongoing Novo Nordisk A/S·Phase 3· NCT07533175
5. Notable: FRONTIERAHA · Research Study Investigating Denecimig (Mim8)…FRONTIERAHA · Research Study Investigating Denecimig (Mim8) · Acquired Haemophilia A Oct 28, 2026 Recruitment opened Novo Nordisk A/S·Phase 3· NCT07830732
6. Notable: Research Study to Evaluate the Safety of NNC4004-0002 When…Research Study to Evaluate the Safety of NNC4004-0002 When Given to · Asymptomatic Hyperuricemia Oct 26, 2026 Primary completion pushed from Jun 1, 2026 to Jan 19, 2027 Novo Nordisk A/S·Phase 1· NCT06859073
7. Notable: See How Safe a New Medicine (NNC0642-1895) is in Healthy People Oct 26, 2026 Recruitment opened Novo Nordisk A/S·Phase 1· NCT07829406
8. Notable: Research Study Investigating How · Overweight or Obesity, With or…Research Study Investigating How · Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication Oct 16, 2026 Recruitment opened Novo Nordisk A/S·Phase 1· NCT07855133
9. Notable: Research Study Investigating How · Overweight or Obesity, With or…Research Study Investigating How · Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication Oct 16, 2026 Recruitment opened Novo Nordisk A/S·Phase 1· NCT07868354

• Stopped: terminated, suspended or withdrawn
• Notable: the plan changed
• Minor: routine updates